July 9th, 2024

---

Company Co-founder Venkat Shastri to Remain Active in Advisory Role

CARLSBAD, CA, July 9, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced the board’s appointment of Chad Holland as the company’s new president and CEO. The appointment comes after Venkat Shastri, company co-founder and former CEO, chose to step aside to take on an advisory role.

“ALZpath is at a pivotal moment of growth,” said Jerre Stead, board chair of ALZpath. “We are excited about our success to date, and we are tremendously grateful to Venkat, under whose leadership our company has reached this point. With Chad as our president and CEO, the support of our board and scientific advisory board, and Venkat’s ongoing counsel, we will continue our successful trajectory, helping to transform the Alzheimer’s care continuum.”

Holland brings a deep skillset in commercialization, business development, and fundraising, perfectly positioning him to accelerate the company’s growth. “We will continue with the successful execution of our pTau217 antibody as the premier reagent for use across diagnostic and research platforms to dramatically improve the outlook for Alzheimer’s patients,” Holland said.

“Looking forward, we will leverage the deep expertise of our team to anticipate and build toward what’s next. This is an incredible time in neurology and neuroscience as we gain new insights to tackle neurodegenerative disorders that until now have been unsolvable.”

 

About ALZpath

ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias. The novel ALZpath pTau217 antibody, integral to the most advanced, widely available blood-based tests to detect Alzheimer’s disease, is transforming its diagnosis and treatment monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. To help millions of patients in need, ALZpath democratizes access to its proprietary robust antibody, which is used by researchers, clinicians, and industry partners around the world to accelerate the discovery of new treatments and improve patient care.

To learn more about the company, please visit https://alzpath.bio/ and follow us on LinkedIn.

ALZpath Media Contact

Nechama Rosengarten

Nechama.Rosengarten@finnpartners.com

+1(551)-444-0784

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on ALZpath’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause ALZpath’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in ALZpath’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, ALZpath assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.